Resmed’s decision to sell MatrixCare to PE firm Frazier Healthcare Partners comes less than a decade after its $750m acquisition of the software business.

VB Spine has signed a definitive agreement with Augmedics to acquire the exclusive rights to the CT-Fluoro technology for spine applications.

Under the deal, Ottobock will inherit Fesia Technology’s portfolio of functional electrical stimulation (FES) products used in neurorehabilitation.

Swiss spine surgery company Neo Medical has commercially launched the Neo Instant MIS Access platform in the US.

The companies will combine their expertise to develop a ‘tuneable’ presbyopia-correcting intraocular lens (PCIOL) for cataract patients.

The company has since learned the cyberattack was caused by a third-party contractor’s user session within its cloud-based system being compromised.

The initiative is designed to simplify the ability for GE HealthCare customers with existing interventional suites to access new technologies.

Funds will support Materna’s completion of a pivotal trial evaluating its system for reducing pelvic floor muscle injury during childbirth, as well as other commercial activities.

Xeltis has reached over 50% enrolment in its US pivotal trial of aXess, a vascular access device designed for adults with end-stage renal disease who require haemodialysis.

Aurenar’s V-Link system uses transauricular vagus nerve stimulation to modulate brain inflammation in patients that have experienced a stroke.

OrthAlign has completed the first clinical procedures using its Lantern ASC system, designed for the ASC setting.

Hyperfine has commercially launched its next-generation Swoop portable MRI system (Model 2) in select European markets.